Copper-Based Single-Atom Nanozyme System Mimicking Platelet Cells for Enhancing the Outcome of Radioimmunotherapy
DOI: https://doi.org/10.2147/ijn.s445805
IF: 7.033
2024-01-16
International Journal of Nanomedicine
Abstract:Cheng Chen, 1, &ast Nandi Chen, 2, 3, &ast Yan Qi, 1, &ast Meng Lyu, 2 Chaoyan Wu, 4, &ast Conghua Xie, 1 Haijun Yu 1 1 Department of Radiation and Medical Oncology, Hubei Province Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, People's Republic of China; 2 Department of Gastrointestinal Surgery & Department of Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, 518020, People's Republic of China; 3 Analysis and Testing Center, Shenzhen Technology University, Shenzhen, 518118, People's Republic of China; 4 Department of Integrated Traditional Chinese Medicine and Western Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, 430071, People's Republic of China &astThese authors contributed equally to this work Correspondence: Haijun Yu; Conghua Xie, Email ; Background: Radiotherapy is an indispensable part of the multidisciplinary treatment of breast cancer (BC). Due to the potential for serious side effects from ionizing radiation in the treatment of breast cancer, which can adversely affect the patient's quality of life, the radiation dose is often limited. This limitation can result in an incomplete eradication of tumors. Methods: In this study, biomimetic copper single-atom catalysts (platelet cell membrane camouflaging, PC) were synthesized with the aim of improving the therapeutic outcomes of radiotherapy for BC. Following guidance to the tumor site facilitated by the platelet cell membrane coating, PC releases a copper single-atom nanozyme (SAzyme). This SAzyme enhances therapeutic effects by generating reactive oxygen species from H 2 O 2 and concurrently inhibiting the self-repair mechanisms of cancer cells through the consumption of intracellular glutathione (GSH) within the tumor microenvironment. PC-augmented radiotherapy induces immunogenic cell death, which triggers an immune response to eradicate tumors. Results: With the excellent biocompatibility, PC exhibited precise tumor-targeting capabilities. Furthermore, when employed in conjunction with radiotherapy, PC showed impressive tumor elimination results through immunological activation. Remarkably, the tumor suppression rate achieved with PC-enhanced radiotherapy reached an impressive 93.6%. Conclusion: Therefore, PC presents an innovative approach for designing radiosensitizers with tumor-specific targeting capabilities, aiming to enhance the therapeutic impact of radiotherapy on BC. Keywords: platelet cell membrane, single-atom nanozyme, radiotherapy, radioimmunotherapy, breast cancer Breast cancer (BC) stands as one of the most frequently diagnosed cancers among females globally. 1 In clinical practice, a combination of surgery, chemotherapy, and radiotherapy is often recommended as adjuvant treatments to achieve more favorable therapeutic outcomes. 2 In particular, post breast-conserving surgery, radiotherapy significantly reduces the rate of tumor recurrence by nearly half. 3,4 Nevertheless, the planning of radiotherapy for breast cancer presents a challenge, as it requires meticulous care to prevent radiation-induced damage to nearby healthy tissues and surrounding organs at risk (OAR). 5,6 Hence, the radiotherapy mice cause severe side effects or raise the risk of secondary cancers due to incomplete elimination of tumors. Another issue linked to recurrence following radiotherapy for breast cancer is the radio-resistance exhibited by tumor cells. 6,7 This resistance is attributed to the complex tumor microenvironment, characterized by conditions such as hypoxia and the overexpression of (GSH) and H 2 O 2 . 8–10 Therefore, in order to attain the desired level of tumor control while also safeguarding normal tissues and organs, it becomes imperative to harness nanotechnology for the effective enhancement of radiotherapy in the treatment of breast cancer. 11,12 Nanozymes, a category of nanostructured materials exhibiting catalytic properties akin to natural enzymes, have garnered considerable interest in various fields such as biosensing, environmental applications, and tumor therapy in recent times. 13–15 In contrast to their natural counterparts, nanozymes offer several advantages, including exceptional stability, cost-effectiveness, and resilience in relatively harsh conditions, making them highly promis -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology